Veterinary Infectious Disease Therapeutics Market

By Type of Infection;

Bacterial Infections, Viral Infections, Fungal Infections, Parasitic Infections, and Mixed Infections

By Product Type;

Antibiotics, Antiviral, Antifungal, Amebicides, and Others

By Animal Type;

Bovine, Horse, Dogs, Poultry, and Others

By End User;

Veterinary Hospitals, Veterinary Clinics, Veterinary Pharmacies, and Research Institutes

By Geography;

North America, Europe, Asia Pacific, Middle East & Africa, and Latin America - Report Timeline (2021 - 2031)
Report ID: Rn104646753 Published Date: August, 2025
Download Free Sample NowDownload Free Sample Now

Veterinary Infectious Disease Therapeutics Market Overview

Veterinary Infectious Disease Therapeutics Market (USD Million

Veterinary Infectious Disease Therapeutics Market was valued at USD 3294.49 million in the year 2024. The size of this market is expected to increase to USD 5290.23 million by the year 2031, while growing at a Compounded Annual Growth Rate (CAGR) of 7.0%.


Veterinary Infectious Disease Therapeutics Market

*Market size in USD million

CAGR 7.0 %


Study Period2025 - 2031
Base Year2024
CAGR (%)7.0 %
Market Size (2024)USD 3294.49 Million
Market Size (2031)USD 5290.23 Million
Market ConcentrationMedium
Report Pages341
3294.49
2024
5290.23
2031

Major Players

  • Elanco Animal Health
  • Novartis Animal Health Inc
  • Merck & Co. Inc.
  • Pfizer Animal Health
  • Sanofi

Market Concentration

Consolidated - Market dominated by 1 - 5 major players

Veterinary Infectious Disease Therapeutics Market

Fragmented - Highly competitive market without dominant players


The Veterinary Infectious Disease Therapeutics Market is growing rapidly as veterinarians and livestock producers emphasize effective prevention and treatment for bacterial, viral, and parasitic infections. With approximately 60% of therapeutic regimens now including targeted antimicrobials, antiviral agents, or parasiticides, this sector is experiencing strong growth. Rising disease awareness and animal welfare standards are creating significant opportunities for innovation and market expansion.

Targeted Molecules Enhancing Treatment Efficacy
Recent technological advancements include long-acting antibiotics, oral antivirals, and next-gen parasiticides with improved safety margins. Nearly 65% of new therapeutics are formulated for reduced dosing frequency and minimal resistance development. These enhancements are driving expansion across small animal clinics, equine facilities, and farm operations.

Collaborative Development Accelerating Pipelines
More than 55% of new therapeutic candidates emerge from collaboration between pharmaceutical companies, veterinary schools, and diagnostic labs. These partnerships support comprehensive clinical trials, real‑world efficacy studies, and streamlined regulatory approval. Strategic merger initiatives further consolidate development capabilities—propelling sustained growth and access.

Smart Delivery Platforms Steering Future Growth
The future outlook centers on innovation in smart delivery systems such as sustained‑release implants, feed-through medicated options, and vaccine-scripted therapeutics. Over 75% of R&D efforts now focus on precision dosing, resistance prevention, and compliance tracking. These technological advancements are poised to sustain long‑term growth and support deep expansion in veterinary infectious disease management.

In this report, the Global Veterinary Infectious Disease Therapeutics Market has been segmented by Type of Infection, Animal Type, End User and Geography.

Veterinary Infectious Disease Therapeutics Market, Segmentation by Type of Infection

The Veterinary Infectious Disease Therapeutics Market has been segmented by Bacterial Infections, Viral Infections, Fungal Infections, Parasitic Infections, and Mixed Infections

Bacterial Infections

Bacterial infections dominate the veterinary infectious disease therapeutics market with a share of about 40%, highlighting the high prevalence of conditions such as mastitis, salmonellosis, and pasteurellosis in livestock. The demand for advanced antibacterial drugs remains strong to ensure improved productivity and animal health.

Viral Infections

Representing nearly 25% of the market, viral infections like avian influenza, canine distemper, and foot-and-mouth disease continue to challenge the livestock and pet sectors. Advances in antiviral therapies are enhancing treatment speed and reducing mortality rates in affected animals.

Fungal Infections

With an estimated 10% share, fungal infections such as aspergillosis and ringworm impact both companion animals and livestock. Growing awareness of early diagnosis and preventive care is driving higher adoption of antifungal treatment solutions.

Parasitic Infections

Parasitic infections account for roughly 15% of the market, driven by widespread issues like helminthiasis, tick-borne diseases, and protozoal infections. Increased emphasis on preventive parasitic control is fueling the demand for advanced veterinary solutions.

Mixed Infections

Holding about 10% of the market, mixed infections involve simultaneous bacterial, viral, or parasitic pathogens. This complexity often requires combination therapies and comprehensive treatment protocols for effective management.

Veterinary Infectious Disease Therapeutics Market, Segmentation by Product Type

The Veterinary Infectious Disease Therapeutics Market has been segmented by Product Type into Antibiotics, Antiviral, Antifungal, Amebicides, and Others.

Antibiotics

Antibiotics dominate the veterinary infectious disease therapeutics market with a share of about 42%, reflecting their essential role in treating bacterial infections in livestock and pets. Their use supports improved animal health and productivity, though regulatory restrictions on overuse are shaping purchasing decisions and market demand.

Antiviral

Holding nearly 18% of the market, the antiviral segment is expanding due to rising cases of viral diseases such as avian influenza and canine parvovirus. Continuous innovation in targeted antiviral solutions is enhancing treatment outcomes and helping veterinarians reduce animal mortality rates.

Antifungal

With an estimated 12% market share, antifungal therapeutics are vital for managing fungal infections like ringworm in companion animals and farm livestock. Increased awareness among pet owners and farmers is boosting the adoption of these treatments for both prevention and cure.

Amebicides

Representing about 8% of the market, amebicides are crucial for addressing protozoal infections such as amoebiasis in farm animals. The segment is benefitting from heightened emphasis on parasitic disease control and preventive animal healthcare practices.

Others

The “Others” category, covering innovative and specialized treatments, accounts for approximately 20% of the market. It includes products like biologics, probiotics, and immune-enhancing formulations designed to strengthen animal immunity and reduce infection risks.

Veterinary Infectious Disease Therapeutics Market, Segmentation by Animal Type

The veterinary infectious disease therapeutics market is segmented by animal type into Bovine, Horse, Dogs, Poultry and Others.

Bovine

Bovine animals lead the veterinary infectious disease therapeutics market with a share of about 38%, underscoring the high prevalence of diseases like mastitis, foot-and-mouth disease, and brucellosis. Effective treatments are essential to safeguard dairy and beef production while maintaining herd health.

Horse

With nearly 12% market share, the horse segment is driven by the need to address infectious diseases such as equine influenza, strangles, and equine herpesvirus. Expansion of the equestrian sports and leisure industry is further increasing demand for high-quality equine therapeutics.

Dogs

Dogs account for approximately 25% of the market, supported by rising pet ownership and the demand for treatments against canine parvovirus, distemper, and tick-borne illnesses. Higher spending on pet healthcare is significantly fueling this category’s growth.

Poultry

Representing around 15% of the market, poultry animals require intensive disease management for conditions like avian influenza, Newcastle disease, and salmonellosis. The growth of commercial poultry farming is boosting adoption of preventive and therapeutic solutions.

Others

The “Others” category holds roughly 10% of the market, including species like cats, sheep, and goats. Demand is driven by targeted treatments designed to address species-specific infectious diseases and enhance overall animal health.

Veterinary Infectious Disease Therapeutics Market, Segmentation by End User

The veterinary infectious disease therapeutics market is segmented by end user into Veterinary hospitals, Veterinary Clinics, Veterinary pharmacies and Research institutes.

Veterinary Hospitals

Veterinary hospitals lead the market with a share of approximately 40%, offering advanced diagnostic tools and specialized expertise for managing infectious diseases in animals. They are the go-to facilities for complex or severe cases requiring comprehensive veterinary care.

Veterinary Clinics

Holding nearly 30% of the market, veterinary clinics serve as the primary healthcare providers for companion animals. They deliver essential services such as vaccinations, disease diagnosis, and treatment for common animal infections, ensuring convenient access to quality care.

Veterinary Pharmacies

Veterinary pharmacies account for about 20% of the market, supplying a wide range of therapeutics to veterinarians and pet owners. The growth of online veterinary pharmacies has improved accessibility and convenience for acquiring essential medications.

Research Institutes

With an estimated 10% share, research institutes play a crucial role in developing new veterinary treatments and preventive solutions. Through research and clinical trials, they contribute significantly to the advancement of animal healthcare and infectious disease management.

Veterinary Infectious Disease Therapeutics Market, Segmentation by Geography

In this report, theVeterinary Infectious Disease Therapeutics Market has been segmented by Geography into five regions; North America, Europe, Asia Pacific, Middle East and Africa and Latin America.

Regions and Countries Analyzed in this Report

Legend
North America
Rest of North America
Europe
Rest of Europe
Asia Pacific
Rest of Asia Pacific
Middle East and Africa
Rest of Middle East and Africa
Latin America
Rest of Latin America
Rest of the World

Veterinary Infectious Disease Therapeutics Market Share (%), by Geographical Region

North America

North America leads the veterinary infectious disease therapeutics market with a share of about 35%, driven by advanced veterinary infrastructure, high pet ownership rates, and significant livestock production. Strong regulatory frameworks support effective disease control and treatment adoption.

Europe

Holding nearly 25% of the market, Europe benefits from robust animal healthcare systems, stringent disease prevention regulations, and rising demand for companion animal care. The region’s focus on high-quality veterinary services continues to boost market expansion.

Asia Pacific

Asia Pacific accounts for approximately 22% of the market, supported by rapid livestock farming growth, increasing animal health awareness, and greater adoption of veterinary therapeutics in key markets such as China, India, and Japan.

Middle East and Africa

With about 10% share, the Middle East and Africa region is experiencing steady growth due to heightened focus on livestock disease management and preventive veterinary care in emerging economies.

Latin America

Latin America represents around 8% of the market, led by Brazil, Argentina, and Mexico. Expanding livestock production and increasing awareness of preventive animal healthcare are fueling demand for veterinary therapeutics.

  1. Introduction
    1. Research Objectives and Assumptions
    2. Research Methodology
    3. Abbreviations
  2. Market Definition & Study Scope
  3. Executive Summary
    1. Market Snapshot, By Type of Infection
    2. Market Snapshot, By Product Type
    3. Market Snapshot, By Animal Type
    4. Market Snapshot, By End User
    5. Market Snapshot, By Region
  4. Veterinary Infectious Disease Therapeutics Market Dynamics
    1. Drivers, Restraints and Opportunities
      1. Drivers
        1. Increasing Global Pet Ownership
        2. Rising Demand for Safe Food Supply
        3. Emerging Zoonotic Diseases
        4. Advancements in Biotechnology
      2. Restraints
        1. Regulatory Hurdles
        2. High Cost of Drug Development
        3. Limited Access in Rural Areas
        4. Antimicrobial Resistance
      3. Opportunities
        1. Expansion in Emerging Markets
        2. Collaborations for Research
        3. Focus on One Health Approach
        4. Development of Novel Vaccines
    2. PEST Analysis
      1. Political Analysis
      2. Economic Analysis
      3. Social Analysis
      4. Technological Analysis
    3. Porter's Analysis
      1. Bargaining Power of Suppliers
      2. Bargaining Power of Buyers
      3. Threat of Substitutes
      4. Threat of New Entrants
      5. Competitive Rivalry
  5. Market Segmentation
    1. Veterinary Infectious Disease Therapeutics Market, By Type of Infection, 2021-2031 (USD Million)
      1. Bacterial Infections
      2. Viral Infections
      3. Fungal Infections
      4. Parasitic Infections
      5. Mixed Infections
    2. Veterinary Infectious Disease Therapeutics Market, By Product Type, 2021-2031 (USD Million)
      1. Antibiotics
      2. Antiviral
      3. Antifungal
      4. Amebicides
      5. Others
    3. Veterinary Infectious Disease Therapeutics Market, By Animal Type, 2021-2031 (USD Million)
      1. Bovine
      2. Horse
      3. Dogs
      4. Poultry
      5. Others
    4. Veterinary Infectious Disease Therapeutics Market, By End User, 2021-2031 (USD Million)
      1. Veterinary hospitals
      2. Veterinary Clinics
      3. Veterinary pharmacies
      4. Research institutes
    5. Global Veterinary Infectious Disease Therapeutics Market, By Geography, 2021-2031 (USD Million)
      1. North America
        1. United States
        2. Canada
      2. Europe
        1. Germany
        2. United Kingdom
        3. France
        4. Italy
        5. Spain
        6. Nordic
        7. Benelux
        8. Rest of Europe
      3. Asia Pacific
        1. Japan
        2. China
        3. India
        4. Australia & New Zealand
        5. South Korea
        6. ASEAN (Association of South East Asian Countries)
        7. Rest of Asia Pacific
      4. Middle East & Africa
        1. GCC
        2. Israel
        3. South Africa
        4. Rest of Middle East & Africa
      5. Latin America
        1. Brazil
        2. Mexico
        3. Argentina
        4. Rest of Latin America
  6. Competitive Landscape
    1. Company Profiles
      1. Elanco Animal Health
      2. Novartis Animal Health Inc
      3. Merck & Co. Inc.
      4. Pfizer Animal Health
      5. Sanofi
  7. Analyst Views
  8. Future Outlook of the Market
Download Free Sample NowDownload Free Sample Now